H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on TScan Therapeutics (TCRX – Research Report) today and set a price target of $15.00.
Andrew Fein’s rating is based on the promising progress TScan Therapeutics has shown in both liquid and solid tumor programs. The company has demonstrated a significant reduction in relapse rates in its TSC-100/101 treatment arm compared to the control group, indicating a strong potential for its therapies. The 70% improvement in event-free survival and the low probability of relapse further support the efficacy of their approach.
Additionally, TScan is advancing its TCR-T therapy programs with key milestones on the horizon, including the expansion of its heme malignancies program and the initiation of a registration trial for TSC-101. The company’s solid tumor program is also progressing, with FDA clearance for multiple TCR-T therapies and plans to dose the first patient with multiplex TCR-T therapy in 2025. These developments, along with the strategic expansion of their ImmunoBank, underscore the potential for TScan’s therapies to achieve regulatory approval and commercial success.
In another report released yesterday, Needham also maintained a Buy rating on the stock with a $9.00 price target.